Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 435.7A |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
4 |
| Average PDX Generation Time (days +/- SEM) | 57 ± 8 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 435.7A |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 435.7A | ZNRF3 | -0.950 | 1.035 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | ZNRF3 | -1.202 | 0.869 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | ZFHX3 | -1.150 | 0.901 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | ZFHX3 | -0.892 | 1.078 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | TP53 | -28.561 | 5.050e-09 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | SUFU | -0.985 | 1.010 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | RB1 | -1.330 | 0.796 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | PIK3CB | 1.128 | 4.372 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | PAX6 | -0.935 | 1.046 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | MGA | -1.054 | 0.964 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | FANCA | -1.138 | 0.909 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | ERBB4 | -0.936 | 1.046 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | CUL3 | -0.936 | 1.046 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | CHD1 | -1.022 | 0.985 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | CDKN1B | -0.999 | 1.001 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | CDH1 | -1.150 | 0.901 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | BRCA2 | -0.986 | 1.010 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 435.7A | APC | -1.022 | 0.985 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 435.7A |
|---|---|
| Sample Site | Front-parietal lobe |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, carboplatin plus etoposide |
Patient Information
| Patient Number | 435 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 16.2 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 435.7A |
| Patient Age (binned in 5 year age groups) | 65-71 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 435.7A | BRCA2 | 194 | 0.98 | Frameshift variant | '11/28 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.7A | SUPV3L1 | 567 | 0.63 | Missense variant | '13/15 | . | 31 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.7A | ATAD2B | 295 | 0.53 | Missense variant | '1/28 | . | 25.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.7A | TSHR | 544 | 0.5 | Missense variant | '11/11 | . | 27.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.7A | IRF4 | 402 | 0.46 | Missense variant | '3/9 | 3.66E-05 | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.7A | NOTCH2 | 493 | 0.43 | Frameshift variant | '34/34 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.7A | PRKDC | 291 | 0.42 | Missense variant | '1/87 | . | 24.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 435.7A | KMT2C | 708 | 0.27 | Stop gained | '16/59 | . | 35 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table